CDMO vs. UROV, GTHX, RIGL, MIRM, PAND, RCKT, CPRX, GLPG, ZLAB, and KROS
Should you be buying Avid Bioservices stock or one of its competitors? The main competitors of Avid Bioservices include Urovant Sciences (UROV), G1 Therapeutics (GTHX), Rigel Pharmaceuticals (RIGL), Mirum Pharmaceuticals (MIRM), Pandion Therapeutics (PAND), Rocket Pharmaceuticals (RCKT), Catalyst Pharmaceuticals (CPRX), Galapagos (GLPG), Zai Lab (ZLAB), and Keros Therapeutics (KROS). These companies are all part of the "medical" sector.
Urovant Sciences (NASDAQ:UROV) and Avid Bioservices (NASDAQ:CDMO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, community ranking, analyst recommendations, dividends, media sentiment and earnings.
18.4% of Urovant Sciences shares are owned by institutional investors. Comparatively, 97.2% of Avid Bioservices shares are owned by institutional investors. 2.7% of Urovant Sciences shares are owned by insiders. Comparatively, 2.4% of Avid Bioservices shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Avid Bioservices has higher revenue and earnings than Urovant Sciences. Avid Bioservices is trading at a lower price-to-earnings ratio than Urovant Sciences, indicating that it is currently the more affordable of the two stocks.
Avid Bioservices has a consensus target price of $14.50, suggesting a potential upside of 82.16%. Given Urovant Sciences' higher probable upside, analysts clearly believe Avid Bioservices is more favorable than Urovant Sciences.
Urovant Sciences has a beta of 2.36, indicating that its stock price is 136% more volatile than the S&P 500. Comparatively, Avid Bioservices has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500.
In the previous week, Avid Bioservices had 2 more articles in the media than Urovant Sciences. MarketBeat recorded 2 mentions for Avid Bioservices and 0 mentions for Urovant Sciences. Urovant Sciences' average media sentiment score of 1.46 beat Avid Bioservices' score of 0.00 indicating that Avid Bioservices is being referred to more favorably in the news media.
Avid Bioservices received 289 more outperform votes than Urovant Sciences when rated by MarketBeat users. Likewise, 66.49% of users gave Avid Bioservices an outperform vote while only 57.35% of users gave Urovant Sciences an outperform vote.
Urovant Sciences has a net margin of 0.00% compared to Urovant Sciences' net margin of -13.10%. Avid Bioservices' return on equity of 0.00% beat Urovant Sciences' return on equity.
Summary
Avid Bioservices beats Urovant Sciences on 11 of the 16 factors compared between the two stocks.
Get Avid Bioservices News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDMO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avid Bioservices Competitors List
Related Companies and Tools
